Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Hereditary angioedema type 3 (HAE 3) is a form of hereditary angioedema characterized by acute edema in subcutaneous tissues, viscera and/or the upper airway.
Features include: Intestinal edema, Angioedema, Episodic abdominal pain, and Vomiting and 3 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Digestive system | 3 | Intestinal edema, Episodic abdominal pain, Vomiting |
Lungs and breathing | 1 | Episodic upper airway obstruction |
Head and neck | 1 | Facial edema |
F12 encodes coagulation factor XII (615 aa). Factor XII is a serum glycoprotein that participates in the initiation of blood coagulation, fibrinolysis, and the generation of bradykinin and angiotensin. Highest expression in Liver (376.0 TPM) and Esophagus Mucosa (10.0 TPM).
Hereditary angioedema type 3 is caused by mutations in the F12 gene on chromosome 5.
The F12 protein participates in F12 T328R(20-328), F12 T328K(20-328), and F12 T328K (329-615) pathways.
F12 is classified as a druggable target (Druggable Genome, Enzyme, and Protease categories) with score 8.7.
Genetic testing for F12 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for hereditary angioedema type 3 has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE2. Research is primarily industry-sponsored.
43 publications have been identified in PubMed for hereditary angioedema type 3. Research spans Review / Meta-Analysis (23%), Case Report / Case Series (19%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 10 | 23% |
Patient case studies | 8 | 19% |
Disease patterns and progression | 8 | 19% |
Clinical study results | 6 | 14% |
Testing and diagnosis research | 5 | 12% |
Laboratory research | 5 | 12% |
Other research | 1 | 2% |
Xu Y (2026). [PMID: 41550678](https://pubmed.ncbi.nlm.nih.gov/41550678/). *World Allergy Organ J*. [Epidemiology / Natural History]
Boch K (2026). [PMID: 41782867](https://pubmed.ncbi.nlm.nih.gov/41782867/). *Front Immunol*. [Epidemiology / Natural History]
Prasad S (2026). [PMID: 42204478](https://pubmed.ncbi.nlm.nih.gov/42204478/). *BMC Gastroenterol*. [Case Report / Case Series]
Gandhi RS (2026). [PMID: 41687928](https://pubmed.ncbi.nlm.nih.gov/41687928/). *J Allergy Clin Immunol*. [Review / Meta-Analysis]
Marquès L (2026). [PMID: 41890722](https://pubmed.ncbi.nlm.nih.gov/41890722/). *Front Immunol*. [Case Report / Case Series]
Dagdelen U (2026). [PMID: 42039318](https://pubmed.ncbi.nlm.nih.gov/42039318/). *Arch Anim Breed*. [Basic Science / Preclinical]
Vázquez DO (2026). [PMID: 42165046](https://pubmed.ncbi.nlm.nih.gov/42165046/). *World Allergy Organ J*. [Review / Meta-Analysis]
Fails JM (2025). [PMID: 40276615](https://pubmed.ncbi.nlm.nih.gov/40276615/). *Kans J Med*. [Case Report / Case Series]
Germenis AE (2025). [PMID: 40599776](https://pubmed.ncbi.nlm.nih.gov/40599776/). *Front Immunol*. [Review / Meta-Analysis]
Zuraw BL (2025). [PMID: 40053270](https://pubmed.ncbi.nlm.nih.gov/40053270/). *Clin Rev Allergy Immunol*. [Review / Meta-Analysis]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 8:49 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
AI-curated news mentioning hereditary angioedema type 3
Updated Feb 6, 2026
BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal to enhance its portfolio with a long-acting preventive therapy for hereditary angioedema. This acquisition reflects a strategic shift in venture firms' preferences as the biotech sector recovers.
Intellia is set to report Phase 3 trial results for a potential treatment for hereditary angioedema in the first half of 2026, amidst a backdrop of significant clinical trial activity in rare diseases. Despite recent challenges, including a study participant's death and program suspensions, the biotech sector is regaining momentum with key readouts expected across various conditions.